News
Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...
News-Medical.Net on MSN3d
Maternal RSV vaccine and nirsevimab sharply cut infant hospitalizations, new data showWidespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...
HealthDay on MSN8d
Nirsevimab Effective for Reducing Burden of RSV in InfantsNirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.
HealthDay on MSN10d
RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked HospitalizationMaternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...
Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.
New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...
Compared with 2018-2020 pooled rates, 2024-2025 RSV-associated hospitalization rates were lower among infants aged 0 to 7 months. HealthDay News — Maternal respiratory syncytial virus (RSV ...
Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden ...
A total of 69 infants (median age at admission, 2.7 months; 56.5% boys) who received nirsevimab and were hospitalised for RSV-related LRTI were included. Cases were classified as breakthrough (n ...
On the heels of a fall and winter that saw hundreds of Alberta babies and toddlers hospitalized and two young children die ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback